Minimally invasive LVAD implantation for advanced heart failure: a single-center retrospective analysis and the promise of minimally invasive approaches Authors: Wang Qingpeng, Cai Jie, Yu Wenjun, Wang Wei, Chen Xing, Liu Jinping Published: 2025 ABSTRACT ObjectiveThis study aimed to preliminarily investigate the feasibility, safety, and early clinical outcomes of minimally invasive left ventricular assist device (LVAD) implantation with concomitant cardiac procedures.MethodsWe retrospectively analyzed the clinical data of three consecutive male patients with end-stage heart failure who underwent minimally invasive LVAD implantation at our center between August and November 2024. Two patients received the CorHeart 6 LVAD, while one received the CH-VAD LVAD. Two patients underwent concomitant procedures (patent foramen ovale closure or left atrial appendage occlusion) during the LVAD implantation.ResultsAll procedures were successfully completed without intraoperative mortality or conversion to sternotomy. Cardiopulmonary bypass time ranged from 121 to 214 min. Postoperative echocardiography demonstrated reduced ventricular dimensions, improved ejection fraction, and resolution of significant valvular regurgitation in all patients. The duration of mechanical ventilation ranged from 1 to 5 days, and the ICU stay ranged from 3 to 7 days. No mortality, pump thrombosis, stroke, or reoperation for bleeding occurred. One patient experienced transient postoperative arrhythmia, which resolved with medical management.ConclusionThis initial experience suggests that minimally invasive LVAD implantation via left thoracotomy, with concomitant cardiac procedures, is technically feasible and safe in selected patients with end-stage heart failure. This strategy was associated with encouraging early outcomes and provides early clinical data on the minimally invasive application of devices such as the CorHeart 6 to the international LVAD community.Keywords: Minimally invasive, LAVD, Retrospective study Introduction Left ventricular assist device (LVAD) is an artificial mechanical device that draws blood from the venous system or the heart and directly pumps it into the arterial system, partially or completely replacing the work of the ventricle. It is primarily used for supportive treatment before cardiac function recovery, as a transitional support treatment before heart transplantation, and for providing permanent assistance to patients who are not suitable for heart transplant [1, 2]. In recent years, the clinical application of LVADs in the field of heart failure has shown rapid growth. Median sternotomy is the classic and currently mainstream surgical method for LVAD implantation, with the main advantages being ease of operation under direct vision, preservation of the pericardium, and reduced adhesion of surrounding tissues; however, it is undeniable that this method is associated with significant trauma, substantial bleeding, and prolonged hospital stays. With the development of minimally invasive cardiac surgery and improvements in LVAD pumps, minimally invasive LVAD implantation has gradually become an inevitable trend in clinical development and a pressing need for patients [3–6]. Minimally invasive LVAD implantation can maintain the integrity of the sternum, reduce intraoperative bleeding [7, 8], lower the risk of postoperative infection, decrease the risk of right heart failure during the perioperative period [9], and improve early survival rates among patients [10]. Additionally, it preserves more possibilities for future heart transplantation [11, 12] or other cardiac surgeries. The Cardiovascular Surgery Department of Zhongnan Hospital of Wuhan University successfully completed three cases of minimally invasive LVAD implantation for advanced heart failure from August to November in 2024. The purpose of this retrospective analysis from our center is to share the clinical experience and technical advantages of three cases of minimally invasive LVAD implantation in patients with advanced heart failure. Methods Patients This study was approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University and obtained informed consent from the patients. From August 2024 to November 2024, three patients with a primary diagnosis of advanced heart failure underwent minimally invasive left ventricular assist device (LVAD) implantation treatment in the cardiovascular surgery department of Zhongnan Hospital of Wuhan University, with clinical data sourced from case records. Operative technique Our cardiac team, comprising experts from the Advanced Heart Failure Unit within the Department of Cardiovascular Surgery at Zhongnan Hospital of Wuhan University, in collaboration with cardiac surgeons, anesthesiologists, and ultrasound specialists, jointly diagnosed patients with end-stage refractory heart failure. Following the criteria for left ventricular assist device (LVAD) implantation [1, 2, 10, 13]: ①patients with end-stage severe heart failure meeting heart transplantation criteria, NYHA class IV, who continue to experience progressive symptoms despite guideline-directed standard treatment for stage D heart failure [2]; ②those who are heavily dependent on positive inotropic agents, have received maximum doses of vasoactive drug therapy, and are severely reliant on intra-aortic balloon pump (IABP), circulatory support pump catheters, and external LVAD [14]; ③patients without severe right heart failure and significant tricuspid regurgitation; ④those with progressive renal and/or liver function deterioration due to decreased perfusion rather than inadequate left ventricular filling pressure (pulmonary capillary wedge pressure ≥ 20 mmHg, and systolic blood pressure ≤ 80–90 mmHg or cardiac index ≤ 2 L•min-1•m-2). The patient was placed in a supine position under general anesthesia, with a single-lumen tracheal intubation. Intraoperative transesophageal echocardiography (TEE) indicated left atrial enlargement, generalized reduction in left ventricular wall motion amplitude, decreased left ventricular systolic function, formation of an apical ventricular aneurysm, and preserved right ventricular wall motion amplitude. Moderate regurgitant signals were observed at the mitral valve orifice, while no significant regurgitant signals were noted at the aortic valve orifice. Incisions were made in the left fifth intercostal space (from the midclavicular line to the anterior axillary line), the right second intercostal space (from the sternum to the midclavicular line), and the right groin (obliquely) to open the skin and subcutaneous tissue, reaching the left and right thoracic cavities and the femoral artery and vein on the right side. A 5 − 0 Prolene purse-string suture was placed on the right femoral artery and vein. The patient was systemically heparinized, and the position of the artificial heart pump was marked at the apex under esophageal ultrasound guidance. Cannulation of the right femoral artery and vein was performed for extracorporeal circulation, with a 3 − 0 Prolene purse-string suture securing the infusion needle at the root. A cruciate incision was made at the abdominal access point, and a cable was guided through. After occlusion of the ascending aorta, the root infusion needle was used to infuse Del Nido solution to induce cardiac arrest. A 3 − 0 Prolene suture with felt was used to intermittently secure the ventricular connector at the apex, followed by an apical incision to install the blood pump. The ascending aorta was opened for venting, and the heart resumed beating in a sinus rhythm. A side clamp was used to occlude part of the ascending aorta, and a 5 − 0 Prolene suture was used to anastomose the artificial blood vessel to the root of the ascending aorta, with intermittent reinforcement of the anastomosis using 5 − 0 Prolene and bovine pericardium. The blood pump was gradually started and vented. After venting the heart, the side clamp was released, and circulatory support was initiated, gradually transitioning to the artificial blood pump, set at 2600 rpm with a flow rate of 4.0 L/min, followed by adjustments for shutdown and removal of the extracorporeal cannula. Protamine was used to neutralize heparin, and vancomycin plus gentamicin were instilled into the pericardial cavity. Left and right chest tubes were placed, and routine closure of the chest was performed, followed by suturing of the subcutaneous tissue and skin. The procedure was smooth, and the patient was safely returned to the ICU after surgery. Table 1 shows that Case 2 and Case 3 perform concomitant patent foramen ovale (PFO) closure and left atrial appendage (LAA) occlusion was based on preoperatively identified high-risk features to mitigate long-term neurological and thromboembolic risks. The primary indication for PFO closure was the confirmation of a significant right-to-left shunt on pre-operative transesophageal echocardiography (TEE). Given that LVAD implantation alters intracardiac hemodynamics, often increasing right-sided pressures, closing a PFO prophylactically is crucial to prevent potential paradoxical embolism and post-operative hypoxemia. The indication for LAA occlusion was rooted in stroke prevention strategy, aligning with guideline recommendations for patients at high thromboembolic risk, aiming to eliminate the primary source of thrombus formation in the setting of required lifelong anticoagulation. Technically, through the minimally invasive left thoracotomy approach, the left atrium was accessed via either a superior roof incision or a dissection along the interatrial groove (Sondergaard’s groove). This exposure allowed for direct visualization and intracardiac repair. The PFO was meticulously closed under direct vision using a continuous or pledgeted suture technique. For the LAA occlusion, an LAA exclusion device (e.g., AtriClip®) was applied at the base of the appendage to achieve secure closure. This combined procedure, performed during a single cross-clamp period, ensured a comprehensive anatomical correction while leveraging the minimal access approach. Table 1Patient’s surgical informationCase 1Case 2Case 3Surgical NameMinimally Invasive Left Ventricular Assist Device (LVAD) ImplantationMinimally Invasive LVAD Implantation + Patent Foramen Ovale (PFO) Closure + ECMO Explantation + Intra-Aortic Balloon Pump (IABP) RemovalMinimally Invasive LVAD Implantation + Patent Foramen Ovale (PFO) Closure + Left Atrial Appendage (LAA) OcclusionSurgical IncisionsLeft 5th intercostal space (midclavicular to anterior axillary line)Right 2nd intercostal space (parasternal to midclavicular line)Right calf (great saphenous vein incision)Left 5th intercostal space (midclavicular to anterior axillary line)Right 2nd intercostal space (parasternal to midclavicular line)Bilateral groin (oblique incisions)Left 5th intercostal space (midclavicular to anterior axillary line)Right 2nd intercostal space (parasternal to midclavicular line)Right groin (oblique incision) Patient’s surgical information Minimally Invasive LVAD Implantation + Patent Foramen Ovale (PFO) Closure + ECMO Explantation + Intra-Aortic Balloon Pump (IABP) Removal Minimally Invasive LVAD Implantation + Patent Foramen Ovale (PFO) Closure + Left Atrial Appendage (LAA) Occlusion Left 5th intercostal space (midclavicular to anterior axillary line) Right 2nd intercostal space (parasternal to midclavicular line) Right calf (great saphenous vein incision) Left 5th intercostal space (midclavicular to anterior axillary line) Right 2nd intercostal space (parasternal to midclavicular line) Bilateral groin (oblique incisions) Left 5th intercostal space (midclavicular to anterior axillary line) Right 2nd intercostal space (parasternal to midclavicular line) Right groin (oblique incision) Postoperative management Postoperatively, the patient was transferred to the Intensive Care Unit (ICU) for continued treatment and early extubation. The treatment included anti-infection therapy, management of left and right heart balance, positive inotropic support, diuretics, nutritional support, maintenance of organ function, and symptomatic support. Results Patient characteristics In This study consecutively enrolled three male patients with end-stage heart failure who underwent minimally invasive left ventricular assist device implantation from August to November in 2024 (Table 2). Case 1 was a 74-year-old elderly patient with a body mass index (BMI) of 25.7 kg/m². He had comorbidities including hypertension, coronary heart disease, and aortic disease. Preoperatively, his INTERMACS class was 3, required inotropic drug support and intra-aortic balloon pump (IABP) support, and was accompanied by severe mitral regurgitation. Case 2 was a 56-year-old patient with a BMI of 24.7 kg/m² and his INTERMACS class was 1, indicating critical illness. Preoperatively, he was dependent on veno-arterial extracorporeal membrane oxygenation (ECMO) and IABP for circulatory support and had comorbid coronary heart disease with severe mitral regurgitation. Case 3 was a relatively young 36-year-old patient with a BMI of 30.3 kg/m² and his INTERMACS class was 3. Although without significant comorbidities, his cardiac function was also in NYHA class IV, accompanied by moderate mitral regurgitation and mild pulmonary hypertension. All patients exhibited varying degrees of atrioventricular valve insufficiency and required preoperative inotropic drug support, representing a typical profile for patients receiving advanced mechanical circulatory support therapy. Table 2Patient’s characteristicsClinical dataCase 1Case 2Case 3GenderMaleMaleMaleAge(years)74.0056.0036.00BMI(kg/m2)25.7024.7030.30HypertensionYNNDiabetesNNNHyperlipidemiaNNNCoronary heart diseaseYYNNYHAⅣⅣⅣAortic diseaseYNNPeripheral vascular diseaseNNNCerebrovascular diseaseNNNRenal DiseasesNNNDigestive System DiseasesYYNPositive inotropic drugYYYICDNNNIABPYYNECMONYNINTERMACS313Smoking historyNYYMRSevereSevereModerateARMildMildMildTRMildMildMild-ModeratePulmonary hypertensionNNMildY: Patients have this disease N: Patients don’t have this disease Patient’s characteristics Y: Patients have this disease N: Patients don’t have this disease Preoperative and postoperative hemodynamics Table 3 displays the hemodynamic results before and after surgery. The hemodynamic parameters for each patient before and after the minimally invasive LVAD implantation are detailed in the table. Postoperatively, all three cases demonstrated notable improvements in systemic perfusion and right heart load without experiencing circulatory instability. Specifically, Case 1 maintained stable mean arterial pressure (MAP: 76 vs. 69 mmHg) and showed a reduction in central venous pressure (CVP: 9 vs. 8 mmHg), indicating improved forward flow and stable right heart function. Case 2, who was critically ill preoperatively, exhibited a significant enhancement in perfusion pressure (MAP: 79 vs. 94 mmHg) alongside stable CVP (11 mmHg) and a marked decrease in systolic pulmonary artery pressure (sPAP: 49 vs. 39 mmHg), reflecting successful unloading of the left ventricle and improved hemodynamic status. Case 3, who presented preoperatively with significantly elevated right heart pressures (CVP: 24 mmHg; sPAP: 50 mmHg), experienced a dramatic normalization post-LVAD (CVP: 6 mmHg; sPAP: 34 mmHg), while maintaining adequate MAP (95 vs. 82 mmHg). Importantly, the mixed venous oxygen saturation (SvO2) stabilized or improved in all patients postoperatively, and cardiac index/cardiac output was maintained within an acceptable range. The consistent trajectory of these changes—characterized by improved perfusion, reduced ventricular filling pressures, and the absence of drastic fluctuations—underscores the effectiveness of the minimally invasive LVAD implantation in achieving immediate hemodynamic stabilization and improvement in these three patients. Table 3Patient’s pre- and post-operative hemodynamic parametersPreoperativePostoperativeCase 1Case 2Case 3Case 1Case 2Case 3MAP(mmHg)76.0079.0095.0069.0094.0082.00CVP(mmHg)9.0011.0024.008.0011.006.00sPAP(mmHg)29.0049.0050.0030.0039.0034.00mPAP(mmHg)19.0021.0022.0020.0022.0015.00PCWP(mmHg)17.0012.0027.0025.0022.0028.00SaO297.60100.00100.0099.00100.00100.00SvO250.0072.6050.0049.0054.0052.00CI3.902.603.503.203.603.40CO6.705.006.305.805.106.00 Patient’s pre- and post-operative hemodynamic parameters Table 4 displays the echocardiographic results before and after surgery. Postoperative echocardiographic findings demonstrated effectively improvements in cardiac structure and function across all three patients following minimally invasive LVAD implantation. In Case 1, left ventricular end-diastolic dimension (LVEDD) decreased from 5.7 cm to 5.2 cm, and the ejection fraction (EF) improved from 37% to 46%, accompanied by the resolution of severe mitral regurgitation (MR). Case 2 showed a reduction in LVEDD from 5.5 cm to 4.8 cm, an increase in EF from 29% to 45%, and complete elimination of severe MR. Case 3, who had the most dilated left ventricle preoperatively (LVEDD 6.7 cm), exhibited a reduction to 6.2 cm post-LVAD, with EF improving from 25% to 36% and moderate MR becoming trivial. A consistent trend of reverse remodeling was observed, characterized by reductions in left atrial size and ventricular wall thickness. Furthermore, the peak velocity of mitral inflow (MVE) decreased in all cases, indicating improved left ventricular unloading. Notably, significant valvular insufficiencies (MR, AR, TR) present preoperatively were eliminated or markedly reduced to trivial levels after the operation. These echocardiographic changes collectively indicate successful ventricular unloading, promotion of reverse cardiac remodeling, and significant hemodynamic improvement following the minimally invasive LVAD implantation. Table 4Patient’s pre- and post-operative echocardiographic parametersPreoperativePostoperativeCase 1Case 2Case 3Case 1Case 2Case 3LA (cm)4.504.204.404.404.004.60LV (cm)5.705.506.705.204.806.20IVS (cm)1.301.101.201.001.001.10LVPW1.201.301.101.001.101.10RA (cm)5.004.604.504.004.003.30RV (cm)4.904.503.703.504.003.80EF%37.0029.0025.0046.0045.0036.00FS%18.0013.0011.0023.0020.0018.00MVE(m/s)1.201.101.100.800.700.70AV(m/s)1.201.100.800.800.800.60PV(m/s)0.800.800.700.600.700.80PA(mmHg)2.502.402.402.302.302.30MRSevereSevereModerateNNNARMildMildMildNNNTRMildMildMild-ModerateNNNY: Patients have this disease N: Patients don’t have this disease Patient’s pre- and post-operative echocardiographic parameters Y: Patients have this disease N: Patients don’t have this disease Operation and clinical results The perioperative and postoperative outcomes for the three patients undergoing minimally invasive LVAD implantation are described as follows (Table 5). All procedures were successfully completed without conversion to sternotomy. Case 1 (Corheart® 6) had an operation time of 240 min, a cardiopulmonary bypass (CPB) time of 121 min, and an aortic occlusion time of 49 min, with an intraoperative blood loss of 600 ml. The patient required 3 days of mechanical ventilation and had a 5-day ICU stay, and was discharged without any postoperative complications. Case 2 (Corheart® 6) required a longer operation time (315 min) and CPB time (172 min), with an aortic occlusion time of 64 min. The intraoperative blood loss was 500 ml. This patient required mechanical ventilation for 5 days and had an ICU stay of 7 days; postoperative transient arrhythmia occurred but was successfully managed medically, and no other complications were noted. Case 3 (CH-VAD) had the longest operation time (380 min) and CPB time (214 min), with an aortic occlusion time of 111 min, but intraoperative blood loss was controlled at 500 ml. This patient demonstrated the most rapid recovery, with only 1 day of mechanical ventilation and a 3-day ICU stay, and was discharged without any complications. Critically, no patient suffered mortality, required secondary thoracotomy, or experienced major adverse events such as gastrointestinal bleeding or pump thrombosis. The overall outcomes highlight the technical feasibility and favorable safety profile of the minimally invasive approach, facilitating stable postoperative recovery in all three cases. Table 5Patient’s intraoperative and postoperative parametersCase 1Case 2Case 3LVAD TypeCorheart® 6Corheart® 6CH-VADOperation Time(min)240.00315.00380.00Cardiopulmonary Bypass Time(min)121.00172.00214.00Aortic Occlusion Time(min)49.0064.00111.00Intraoperative Blood Loss(ml)600.00500.00500.00ICU Time(days)5.007.003.00Duration of Mechanical Ventilation (Days)3.005.001.00Postoperative ComplicationsNNNDeathNNNArrhythmiaNYNSecondary ThoracotomyNNNGastrointestinal BleedingNNNThrombosisNNNY: Patients have this disease N: Patients don’t have this disease Patient’s intraoperative and postoperative parameters Y: Patients have this disease N: Patients don’t have this disease Discussion The conventional implantation of a left ventricular assist device (LVAD) is typically conducted via a median sternotomy accompanied by cardiac arrest, representing the standard surgical method in contemporary practice. This method provides excellent surgical exposure for the implanted pump, maintains complete coverage of the heart during the procedure, reduces adhesion to surrounding tissues, ensures hemodynamic stability, allows for thorough examination of the left heart structures, facilitates venting, and can correct intracardiac abnormalities simultaneously. However, it is undeniable that this technique is highly invasive, associated with significant intraoperative bleeding, a high risk of infection, and prolonged hospital stays for patients. Additionally, it carries risks such as blood dilution, coagulation dysfunction, systemic inflammatory response, increased pulmonary artery pressure, and right heart failure [15]. With the development of minimally invasive cardiac surgery and the miniaturization of third-generation LVAD pumps, minimally invasive LVAD implantation techniques have become a trend in clinical practice and a pressing need for patients [3–5, 16–20]. In three instances of minimally invasive left ventricular assist device (LVAD) implantation successfully conducted at our center, metrics including surgical duration, anesthesia duration, extracorporeal circulation time, blood loss, length of ICU stay, and duration of mechanical ventilation were all significantly shortened or improved compared to traditional open-heart surgery. During the surgical procedure, We found that compared to conventional open-heart surgery [16], minimally invasive LVAD implantation not only preserves the integrity of the sternum and allows for the LVAD pump to be implanted through a small incision [16, 21], thereby minimizing surgical trauma, but also effectively avoids myocardial ischemia-reperfusion injury, reduces intraoperative blood loss and the use of blood products [7, 8] and shortens the duration of positive inotropic drug use [8, 22], while decreasing the risk of wound infection [21]. Additionally, after the surgery, we also found that the patient’s sternum remained intact, with only a 2-centimeter incision under the left rib. It preserves more anatomical options for future heart transplantation or other cardiac surgeries. Postoperatively, patients recover well and can mobilize early [23], shortening the recovery period and hospital stay [22, 24]. Furthermore, it is learned that the implantation of the LVAD pump provides stable hemodynamic support to maintain the function of terminal organs [25]and can also be used for support therapy prior to cardiac function recovery, transitional support therapy while waiting for heart transplantation [12, 26] and permanent assistive treatment for patients who are not suitable candidates for heart transplantation [11]. The minimally invasive implantation of LVAD can be conducted while the heart remains beating [27, 28], a technique that significantly mitigates cardiac damage, reduces perioperative complications, and enhances long-term outcomes. While the standard LVAD implantation procedure is typically performed on the beating heart without aortic cross-clamping, our surgical strategy in this series involved the short-term cardiac arrest. This technical decision was driven by the specific clinical characteristics of our patient cohort and the requirement for concomitant intracardiac procedures. Specifically, two of the three patients presented with complex cardiac pathologies that necessitated precise intervention under direct visualization: one required patent foramen ovale (PFO) closure to prevent potential post-operative right-to-left shunting, and another required left atrial appendage (LAA) occlusion to mitigate the long-term risk of thromboembolism. Given the constraints of the minimally invasive approach, which offers a limited surgical field, we determined that a brief period of cardioplegic arrest would provide an optimal, motionless operative environment. This was crucial to ensure the accuracy and safety of these additional delicate procedures, which involved manipulation within the left atrium. Therefore, the use of aortic cross-clamping was not a routine practice for isolated LVAD implantation at our center, but rather a tailored, patient-specific strategy to address unique anatomical challenges and achieve comprehensive treatment in a single operation. Moreover, maintaining cardiac activity ensures adequate filling of the left ventricle. Additionally, we use a left intercostal incision can enhance apical suspension, thereby facilitating more effective gas evacuation and reducing the risk of gas embolism during the perioperative period. A pertinent comparison between the Corheart 6 and the more widely documented HeartMate 3 LVADs reveals important technical nuances when employing a minimally invasive left thoracotomy approach [29, 30]. The primary distinctions lie in device-specific characteristics and their implications for implantation. The Corheart 6 pump is notably smaller and lighter, featuring a fully magnetically levitated design with a distinct inflow cannula angle. These attributes influence the surgical technique within the confined space of a minimally invasive field. Specifically, the smaller pump profile and different spatial orientation may offer greater flexibility in positioning the pump within the pericardial space and can facilitate the anastomosis of the outflow graft to the aorta, potentially simplifying the procedure compared to bulkier devices.While the fundamental surgical access via left thoracotomy remains consistent, the unique geometry of the Corheart 6 may necessitate subtle adaptations in the exact incision placement and the strategy for establishing cardiopulmonary bypass to optimize exposure. Our initial experience with successful implantations provides preliminary but crucial evidence for the feasibility of implanting the Corheart 6 via this approach. This finding is complementary to the large body of evidence supporting the safety and efficacy of the minimally invasive left thoracotomy technique established with the HeartMate 3. The principal contribution of this case series lies in its documentation of the initial experience with minimally invasive implantation of the CorHeart 6 ventricular assist device—a technologically advanced, compact, fully magnetically levitated pump that currently has limited international exposure outside of China. Our successful application of this device in two patients via a left thoracotomy approach provides valuable preliminary evidence regarding its technical feasibility and implant characteristics. Specifically, we observed that the device’s minimal footprint and integrated inflow conduit geometry facilitated optimal positioning within the pericardial space and simplified outflow graft anastomosis through limited incisions. While the general principles of minimally invasive LVAD implantation are increasingly established, the device-specific technical considerations for the CorHeart 6 remain sparsely documented in global literature [31]. Therefore, this report serves to introduce this novel device to the international surgical community and demonstrates that the recognized advantages of minimally invasive implantation can be successfully extended to this promising technology. These early experiences provide a foundational reference for centers considering the adoption of the CorHeart 6 and contribute to the growing armamentarium of mechanical circulatory support options. Importantly, we think that one of the most challenging issues associated with LVAD implantation is the postoperative balance between the left and right heart [26, 32], This includes problems such as changes in preload and afterload, increased right ventricular pressure, fluid imbalance, hemodynamic monitoring, and uneven mechanical loading [26]. However, minimally invasive LVAD implantation can reduce the risk of right heart failure during the perioperative period [9, 26, 33–35], mainly for the following reasons: (1) Minimally invasive surgical techniques use smaller incisions, reducing mechanical damage to the thoracic cavity and heart, which helps protect right heart function. (2) During the surgery, intraoperative ultrasound and observation of hemodynamic parameters allow for timely assessment of cardiac function, enabling adjustments to LVAD parameters to optimize blood flow balance between the left and right heart [25]. (3) Based on the specific cardiac function status of the patient, the speed of the LVAD can be adjusted to ensure that blood flow meets the body’s needs, thereby reducing the burden on the right heart. (4) Minimally invasive techniques decrease the incidence of perioperative complications [36], lowering the risk of postoperative right heart failure and thus facilitating the balance of cardiac function [37]. (5) Postoperatively, closely monitoring and managing the patient’s fluid status, medication use, and cardiac function evaluation helps maintain overall cardiac balance. (6) Patients typically recover quickly after minimally invasive surgery, but attention must still be paid to the burden on the right heart, optimizing fluid intake, medication, and rehabilitation plans to maintain overall cardiac function. Minimally invasive LVAD implantation surgery effectively enhances the likelihood of achieving balance between the left and right heart by reducing trauma and complications, combined with personalized management approaches [33]. This represents a significant advancement in the field of cardiac surgery in recent years. Minimally invasive LVAD implantation can also improve early survival rates for patients [38], particularly for critically ill patients with advanced heart failure [38], we had completed three cases: the elderly and those with high body weight [39, 40], as well as patients on IABP + ECMO [14]. This procedure effectively reduces perioperative complications for these patients, including the risks of postoperative infection, bleeding, and other complications [36]. Due to the smaller incision, patients typically recover faster and return to their daily lives more quickly, which helps improve postoperative survival rates. Minimally invasive LVAD surgery can support cardiac function earlier, reduce the burden of heart failure, and rapidly improve the patient’s hemodynamic status, promoting the recovery of multiple organ functions. Real-time monitoring of hemodynamic changes during the procedure aids in timely adjustments to LVAD parameters, providing stable blood flow, reducing cardiac load, and preventing the worsening of heart failure. In minimally invasive surgeries, doctors can develop more personalized surgical and postoperative management plans based on the specific conditions of the patient, optimizing efficacy and minimizing risks. The advantages of minimally invasive surgery include shorter hospital admission and stay times, which contribute to the recovery of mental health, while also alleviating the economic burden and psychological stress on patients and their families, thereby enhancing the overall survival capacity of patients. Therefore, minimally invasive LVAD implantation offers a safer and more effective treatment option for critically ill patients with advanced heart failure, significantly improving early survival rates [41]. While the small cohort size precludes formal statistical validation, the observed trends in key perioperative metrics—such as operative time, duration of mechanical ventilation, and length of ICU stay—align with the advantages commonly associated with minimally invasive left ventricular assist device (LVAD) implantation reported in the literature [35, 42, 43]. More importantly, this study provides an in-depth examination of the unique technical challenges inherent in this approach, including obtaining adequate exposure through limited incisions and managing concomitant procedures in a confined surgical field. We have also openly addressed the associated learning curve, noting improvements in efficiency and team coordination with accumulated experience. The value of this preliminary single-center experience lies not in claiming superiority, but in offering practical insights into the initial implementation of this technique. By transparently sharing our procedural refinements and management strategies, this report aims to contribute meaningful real-world data to the field, assisting other centers in navigating the complexities of adopting minimally invasive LVAD therapy. However, consistent with the results reported by most centers, there is no significant difference in mid- to long-term survival rates between minimally invasive and median sternotomy approaches [7, 36], The purpose of this article is to analyze the technical advantages and clinical experience of minimally invasive LVAD implantation. With the development of minimally invasive cardiac surgery and the improvement and updating of LVAD pumps, minimally invasive LVAD implantation techniques are gradually becoming a trend in clinical practice and a practical need for patients [5, 6]. Compared to traditional open-heart surgery, the learning curve for minimally invasive LVAD implantation techniques is long and the learning difficulty is high [44–46], This approach requires a well-coordinated team and highly specialized skills [46], and it emphasizes the importance of preoperative technical planning as well as postoperative care and monitoring. As long as the team is experienced, the skills are proficient, there is sufficient multidisciplinary discussion before the operation, tight monitoring during the procedure to reduce risks, and enhanced care after surgery, minimally invasive LVAD implantation remains a safe, effective, and feasible method for treating advanced heart failure [19, 36, 47]. Our institutional experience with minimally invasive LVAD implantation must be contextualized within the contemporary framework established by recent international guidelines. The 2023 EACTS Expert Consensus and the ISHLT MCS Guidelines [48, 49] both emphasize a patient-tailored approach to surgical strategy, which aligns with our selection of a left thoracotomy approach for patients deemed suitable for a less invasive procedure. Our patient selection, focusing on individuals without prior sternotomy and with favorable anatomy, reflects the guidelines’ emphasis on optimizing surgical risk and potential for recovery. Furthermore, our anticoagulation protocol, initiated post-operatively with heparin and transitioned to vitamin K antagonists, was meticulously managed in accordance with the recommended therapeutic targets for LVAD patients outlined in these documents to balance thromboembolic and bleeding risks. While our cohort is small, the congruence of our management strategies with these expert consensus recommendations strengthens the validity of our preliminary findings. It demonstrates that even in its early stages, a structured program can successfully adhere to international standards. This alignment suggests that the favorable outcomes we observed—particularly the absence of pump thrombosis or major hemorrhagic events—are not incidental but are likely attributable to the rigorous application of evidence-based principles. Thus, our report contributes by illustrating the successful translation of contemporary guideline recommendations into clinical practice within a single-center setting, specifically applying them to the emerging Corheart 6 device. Conclusions The implantation of a minimally invasive LVAD for patients with advanced heart failure is a safe and effective surgical method that can improve symptoms, reduce complications, lower the risk of perioperative right heart failure, and enhance early survival rates. Limitations The limitations of this study include a small number of cases, a short follow-up period, and the lack of comparative analysis between patients undergoing open chest and minimally invasive surgery. Acknowledgements We thank for the support of National Natural Science Foundation of China (No. 82470421). We declare that this manuscript has not been published elsewhere, in whole or in part, and has not been presented at any scientific meeting, including in abstract form. Author contributions (I) Conception and design: Chen Xing and Liu Jinping; (II) Administrative support: Liu Jinping; (III) Provision of study materials or patients: Cai Jie and Yu Wenjun; (IV) Collection and assembly of data: Wang Qingpeng and Wang Wei; (V) Data analysis and interpretation: Wang Qingpeng; (VI) All authors contributed to the manuscript writing and final approval of manuscript. Funding This research was supported by the National Natural Science Foundation of China (No. 82470421). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wang Qingpeng and Cai Jie have equally contributions. Contributor Information Chen Xing, Email: chenxing2022@whu.edu.cn. Liu Jinping, Email: liujinping@znhospital.cn. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.